~~<i id='200F839555'><strike id='200F839555'><tt id='200F839555'><pre id='200F839555'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

leisure time

author：hotspot 2025-09-02 11:47:52 - browse：3

The Food and Drug Administration on Thursday approved a gene therapy to treat people with hemophilia A, an inherited and rare bleeding disorder.

The treatment, called Roctavian, is made by BioMarin Pharmaceutical. It was first approved in Europe in August 2022.

Roctavian is a one-time therapy that, in clinical trials, dramatically reduced bleeding episodes and helped patients live without the blood transfusions used to treat the disease. The FDA first rejected Roctavian in 2020, asking BioMarin to amass more data on its safety and long-term durability, and then delayed its decision again to account for additional evidence.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： The Harvard botanist who searched for psychedelics in the Amazon

Wikipedia

knowledge

focus

Wikipedia

focus

MichaelConroy/APThesedays,thesurefirewaytogetaheadinhealthinsuranceistobecomeahealthcareprovider,and

WSS

First recipient of genetically engineered pig kidney has died

Apple Watch's A

A new nitrogen execution bill also undermines medical licensing

Ed Silverman on new gene therapies, biosimilars, coffee, and more

Alabama hospital puts IVF treatments on hold

In utero gene editing: an explainer

knowledge

leisure time

Wikipedia

DIEP, the 'gold standard' of breast reconstruction, is under threat

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

Tori Bowie and the unacceptable rates of Black maternal death

R1 RCM gets $5.8 billion buyout offer from private equity firm

Affirmative action in medical school literally saved lives

R1 RCM gets $5.8 billion buyout offer from private equity firm

Medical leaders decry Supreme Court decision on affirmative action

R1 RCM gets $5.8 billion buyout offer from private equity firm

Alkermes shareholders re

Readout LOUD podcast: brain research, obesity drug sales, Novartis

Wikipedia

Community Health Systems hospitals under DOJ investigation

Study: Adult vaccinations pay for themselves in societal benefits

Study: Adult vaccinations pay for themselves in societal benefits

Alabama IVF ruling threatens families facing fatal genetic disease

What nurses really want: sufficient staffing for patient care

6 phony surgeries that take placebo to the extreme

knowledge

focus

Wikipedia

focus